Patent US5081029A successfully refreshed from Google Patents.
US5081029A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of adoptive immunotherapy for treatment of aids
Assignee: Oncogen LP
•
Filing: 1989-02-01
•
Granted: 1992-01-14
•
Expires: 2009-02-01
Abstract
Abstract Immunotherapeutic methods for the treatment of patients infected with the AIDS virus are described. T lymphocytes which are histocompatible with the patient and specific for the AIDS virus are activated in vitro by exposure to AIDS virus-related epitopes. Activated T lymphocytes are expanded and inoculated into the patient in order to transfer T cell immunity directed against the AIDS virus epitopes.
Inventors
- 👤 Joyce M. Zarling
- 👤 Shiu-Lok Hu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 18:09
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K40/00; A61K40/10; A61K40/11; A61K40/40; A61K40/46; C07; C07K; C07K14/00; C07K14/005; C12N2710/00; C12N2710/00011; C12N2710/14011; C12N2710/14111; C12N2710/14141; C12N2710/14143; C12N2710/24011; C12N2710/24111; C12N2710/24141; C12N2710/24143; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16022; C12N2740/16211; C12N2740/16234
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
50 words
A method for activating T-lymphocytes specific for the AIDS virus in vitro, comprising exposing lymphocytes, derived from an individual who was previously exposed to an AIDS-virus envelope protein or fragment thereof, to the AIDS-virus envelope protein or fragment thereof in vitro, so that T-lymphocytes specific for the AIDS-virus are activated.
Claim 2
Independent Claim
50 words
A method for activating T-lymphocytes specific for the AIDS virus in vitro, comprising exposing lymphocytes, derived from an individual who was previously exposed to an AIDS-virus envelope protein or fragment thereof, to the AIDS-virus envelope protein or fragment thereof in vitro, so that T-lymphocytes specific for the AIDS-virus are activated.
Claim 3
Dependent Claim
87 words
The method according to claim 1 further comprising the steps of selecting activated T-lymphocytes by either of the following assays: (i) a cytotoxicity assay in which the activated T-lymphocytes are incubated with the persons's radiolabelled target cells infected with AIDS virus, the release of radiolabel being an indication of lysis of the infected target cells; or (ii) a stimulation assay which measures the ability of the activated T-lymphocytes to proliferate and/or produce a lymphokine in response to stimulation with an epitope of the AIDS virus in vitro.
Claim 4
Dependent Claim
30 words
The method according to claim 1 or 42 in which T-Lymphocytes are activated in vitro by exposure to a recombinant microorganism that expresses an AIDS-virus envelope protein or fragment thereof.
Claim 5
Dependent Claim
15 words
The method according to claim 3 in which the recombinant microorganism comprises a recombinant virus.
Claim 6
Dependent Claim
15 words
The method according to claim 4 in which the recombinant virus comprises an animal virus.
Claim 7
Dependent Claim
15 words
The method according to claim 5 in which the animal virus comprises a vaccinia virus.
Claim 8
Dependent Claim
15 words
The method according to claim 4 in which the recombinant virus comprises an insect virus.
Claim 9
Dependent Claim
14 words
The method according to claim 7 in which the insect virus comprises a baculovirus.
Claim 10
Dependent Claim
27 words
The method according to claim 4 in which the T-lymphocytes are activated by exposure to v-env5 as deposited with the ATCC and assigned accession number ATCC VR2113.
Claim 11
Dependent Claim
24 words
The method according to claim 4 in which the recombinant virus is v-env5NY as deposited with the ATCC and assigned accession number ATCC VR2149.
Claim 12
Dependent Claim
24 words
The method according to claim 4 in which the recombinant virus is Ac-env5 as deposited with the ATCC and assigned accession number ATCC VR2151.
Claim 13
Dependent Claim
19 words
The method according to claim 1 or 2 in which the person was previously exposed to the AIDS virus.
Claim 14
Dependent Claim
23 words
The method according to claim 1 or 2 in which the person was previously exposed to the AIDS envelope protein or fragments thereof.
Claim 15
Dependent Claim
28 words
The method according to claim 1 or 2 in which the person was previously exposed to a recombinant virus that expresses the AIDS envelope protein or fragments thereof.
Claim 16
Dependent Claim
28 words
The method according to claim 1 or 2 in which the person was previously exposed to V-env5 as deposited with the ATCC and assigned accession number ATCC VR2113.
Claim 17
Dependent Claim
28 words
The method according to claim 1 or 2 in which the person was previously exposed to v-env5NY as deposited with the ATCC and assigned accession number ATCC VR2149.
Claim 18
Dependent Claim
28 words
The method according to claim 1 or 2 in which the person was previously exposed to AC-env5 as deposited with the ATCC and assigned accession number ATCC Vr2151.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-13 | 1995-07-15 | 1996-01-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-13 | 1999-07-15 | 2000-01-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-13 | 2003-07-15 | 2004-01-14 | $7700.00 | Window Closed / Lapsed |